Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Sorrento Therapeutics Dropped 16.6% Today

By Brian Orelli, PhD – May 19, 2020 at 7:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

What goes up, must come down.

What happened

After jumping as much as 282% from Thursday's closing price to the high yesterday, Sorrento Therapeutics (SRNE -2.58%) dropped 16.6% on Tuesday on no apparent news -- other than, of course, that the biotech had jumped a 282% in less than two trading days, followed by a dose of reality as it closed down yesterday and down even more today.

So what

On Friday, shares of the company more than doubled as Sorrento reported that it had found an antibody, STI-1499, capable of binding and neutralizing the coronavirus that causes COVID-19.

Scientist working in a laboratory

Image source: Getty Images.

The issue, of course, is that the results were measured in a test tube. Inhibiting the virus in a laboratory is a good first step, but what ultimately matters is whether the drug works in patients, and Sorrento Therapeutics is a way away from having clinical trial data showing STI-1499 can actually help patients that have COVID-19 and eventually gain regulatory approval,

And Sorrento Therapeutics has plenty of competition. Regeneron Pharmaceuticals (REGN -1.61%) and Vir Biotechnology (VIR -1.77%) are also developing antibody treatments to attack the coronavirus that leads to COVID-19.

Now what

With vaccines already in clinical trials, it seems very risky to invest in preclincial treatments for COVID-19 that need to get through the clinical trial process and gain regulatory approval before potential patients start getting protected by a vaccine.

Investors would be better off looking at Sorrento Therapeutics' long-term prospects beyond STI-1499, but unfortunately the prospects appear fairly limited. The company has one drug, ZTlido, on the market, but with sales around $5 million per quarter, that's not exactly paying Sorrento's bills. The company has a couple of other drugs in development, but it's hard to justify Sorrento as a long-term value at these inflated price -- even after today's decline.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
SRNE
$1.51 (-2.58%) $0.04
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$686.10 (-1.61%) $-11.23
Vir Biotechnology, Inc. Stock Quote
Vir Biotechnology, Inc.
VIR
$18.26 (-1.77%) $0.33

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.